Amyotrophic Lateral Sclerosis And/or Frontotemporal Dementia, Behavioral Variant Frontotemporal Dementia, Corticobasal Syndrome, Progressive Nonfluent Aphasia, Progressive Supranuclear Palsy, Semantic Dementia
Conditions
Brief summary
To establish diagnostic tools to make an accurate clinical and pathological diagnosis of patients with clinical FTLD syndromes
Detailed description
The goal of this study is to determine the best diagnostic test for diagnosing frontotemporal lobar degeneration. To accomplish this, the current study will evaluate different tests: brain imaging, skin biopsy, body fluid samples (blood and cerebrospinal fluid), thinking abilities, everyday functioning, and brain autopsy. The study team hopes that this information can be used to guide diagnosis and further understanding of mechanism of disease in Frontotemporal Lobar Degeneration and possibly treatment in the future.
Interventions
OTHERObservational Study
Sponsors
University Health Network, Toronto
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
* Participant must have a reliable study partner who can provide an independent evaluation of functioning. * Able to read, understand and speak English for neuropsychological testing. * All subjects must meet one of these diagnostic criteria (A) probable behavioral variant FTD, (B) MRI-supported non-fluent variant PPA; (C) MRI-supported semantic variant PPA and \[18F\]T807 negative (D) probable CBS: using current criteria for CBS(27); (E) PSP: inclusion criteria for PSP are based upon the National Institute of Neurological Disorders and Stroke Society of Progressive Supranuclear Palsy (NINDS-SPSP) (F) FTD-MND * Control subjects must have a normal neurological exam, a CDR sum of boxes = 0, and MMSE score equal to or greater than 28
Exclusion criteria
* Patients with clinical, imaging or CSF A beta/ tau profile consistent with AD * History of traumatic brain injury, brain tumors, stroke or other neurological or psychiatric disorders that can explain symptoms will be excluded. * Premenopausal women will be asked to consent to a pregnancy test prior to each scan as pregnant women will be excluded from study because of potential harm to fetus from PET study. * Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Structural and Functional Diffferences between the FTLD groups via MRI of the brain | One time visit through study completion of 5 years | Differences in brain volumes and resting state functional connectivity |
| Differences between the FTLD groups via PET imaging of the brain | One time visit through study completion of 5 years | Differences in ligand uptake |
Countries
Canada
Contacts
Primary ContactCristina Salvo, BSc, MD
Outcome results
None listed